First Hawaiian heads into its July 24 earnings report having outrun most of its regional bank peers, while the Street remains firmly in hold-or-sell territory — a tension that sharpens as the stock has now exceeded the analyst consensus target.
The most notable development this week came from JP Morgan, which raised its price target on FHB to $31 from $27 on July 1, even while maintaining an Underweight rating. That move is worth dwelling on: JP Morgan is now pointing to $31 but still recommending clients avoid the stock, effectively acknowledging momentum while refusing to endorse the valuation. The consensus mean target across the Street is $28.44, below the current $29.30 close. That inversion — where the stock trades above the average analyst target — is unusual and typically reflects a market running ahead of fundamental re-ratings. The bull case centres on resilient fee income (~$55.6M last quarter) and EPS growth toward $2.21 over the next three years. Bears counter with falling net interest margins, rising loan loss provisions, and a 6% quarter-over-quarter loan decline that suggests the lending engine is losing momentum.
Short interest tells a moderately bearish but non-extreme story. At 9.5% of the free float, the short position is material — roughly 11.8 million shares — and has climbed about 18% over the past month, even as it edged back 2.9% on the week. The borrow market is nowhere near stressed: availability is running at nearly 1,977% of existing short interest, meaning shares are abundant for anyone wanting to add to a short position. Cost to borrow remains low at 0.36%, down 14% on the week. Nothing in the lending data points to squeeze pressure — if anything, the loose borrow conditions make it cheap and easy to maintain a bearish position heading into the print.
Options positioning has shifted notably less defensive than it has been. The put/call ratio is 2.5 on June 30, well below its 20-day average of 9.9 and sitting roughly one standard deviation below that mean. That's a sharp contrast to the extreme put-heavy readings from May, when the PCR ran as high as 20.35. The unwinding of that defensive overhang coincides with the stock's 8.6% recovery this month. What remains to be seen is whether this shift reflects genuine conviction or simply the rolling off of stale protection.
On a weekly basis, FHB's 2.4% gain put it roughly in line with peers. AUB led the group with a 4.8% week, while UCB and ASB each added around 3%. RNST was the outlier to the downside, slipping 0.5%. FHB's short score has edged down slightly to 54.4 from 55.6 a week ago — a mild softening, consistent with the week's short covering. The ORTEX factor picture underscores the Street's wariness: the forward earnings momentum rank is just 19th percentile, and the short score rank sits at the 6th percentile, suggesting the data broadly agrees with the sceptical analyst consensus even as price action has been firmer.
The July 24 earnings call is now the focal point. With the stock trading above the mean analyst target and JP Morgan's Underweight note fresh, the session following results will test whether the fee income story can outweigh the NIM and loan-growth concerns that dominate the bear case.
See the live data behind this article on ORTEX.
Open FHB on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
